Zelluna names MaSTherCell as CDMO to support immunotherapy development – OutSourcing-Pharma.com
OutSourcing-Pharma.com |
Zelluna names MaSTherCell as CDMO to support immunotherapy development
OutSourcing-Pharma.com Zelluna Immunotherapy has partnered with the CDMO MasSTherCell to develop its T-cell receptor (TCR) adoptive cell therapy platform with clinical trials expected to begin in 2019. The biotechnology company Zelluna, which specializes in TCR-based … |
